Coronary Artery Disease (CAD)
Conditions
Keywords
orbital atherectomy system, rotational atherectomy, Fractional flow reserve, coronary flow reserve, index of microcirculatory resistance (IMR)
Brief summary
The investigators hypothesize that the orbital atherectomy system (OAS), a newer generation atherectomy device, reduces the incidence of microcirculatory compromise as compared to older generation rotational atherectomy (RA) due to differences in the mechanism of athero-ablation.
Detailed description
The presence of heavily calcified coronary lesions necessitates the use of ablative devices that aid in successful percutaneous coronary intervention (PCI). However, atherectomy devices generate microparticles that embolize to the distal coronary microcirculation and may compromise myocardial tissue perfusion. Two mechanisms that deserve particular attention are the eccentric mounting of the OAS crown and the higher flow rates on the vasodilator flush. Firstly, as opposed to rotational atherectomy where the larger, centrally mounted burr may cause obstruction of flow during the atherectomy, the smaller eccentrically mounted crown in OAS allows continuous perfusion during both atherectomy as well as rest periods. Second, both during rest and atherectomy, the flow rates of vasodilatory flush is higher in OAS compared to RA. Combined, these differences in coronary and vasodilator flush flow could lead to improved perfusion of the distal circulation, particularly during the atherectomy runs when risk of embolization is highest. The loss of microcirculatory function can be transient, with partial or complete restoration of microcirculatory blood flow, or permanent. As shown in studies of patients with acute coronary syndromes, the loss of microcirculatory function is a critical and independent predictor of myocardial recovery and adverse outcomes. The putative protective effects of OAS on coronary microvasculature may therefore be of major clinical significance and impact.
Interventions
DEVICEOrbital Atherectomy System (OAS)
The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
PROCEDUREMagnetic Resonance Imaging (MRI)
In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
Sponsors
Columbia University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Patient with an indication for PCI including: * Angina (stable or unstable), * Silent ischemia (a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), * Non-ST Segment Elevation Myocardial Infarction (NSTEMI) 3. Patients will undergo cardiac catheterization and possible or definite PCI with intent to stent using any non-investigational metallic drug-eluting stent (DES) 4. Signed written informed consent 5. Heavily calcified (severe)lesions necessitating atherectomy. Angiographic inclusion criteria: 1. The target lesion must be located in a native coronary artery with visually estimated reference vessel diameter of ≥2.25 mm to ≤4.00 mm. 2. Lesion length between 20 mm and 50mm
Exclusion criteria
1. Estimated creatinine clearance \<30 ml/min using Cockcroft-Gault equation, unless the patient is on dialysis; 2. ST-elevation Myocardial Infarction (STEMI) within 24 hours of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital. 3. PCI within 24 hours preceding the study procedure. 4. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure \<90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including intra-aortic balloon pump (IABP), at time of procedure. 5. Mobitz II second degree or complete heart block 6. Malignant ventricular arrhythmias requiring treatment 7. Pulmonary edema defined as patient with shortness of breath, evidence of volume overload on physical exam, and crepitations on physical exam (\>1/3 of lungs) or radiographic interstitial or alveolar pulmonary edema 8. Subject is intubated. 9. Known left ventricular ejection fraction (LVEF) \<35%. 10. Severe valvular disease (e.g. severe mitral regurgitation or severe aortic stenosis) 11. Patient is participating in any other investigational drug or device clinical trial that has not reached its primary endpoint. 12. Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test within one week before treatment). General Inclusion - MRI Sub-Study 1. Patients with no prior MI/scarring in the subtended myocardial territory. 2. Patients with no contraindication for MRI studies 3. Patients who could safely receive Gadolinium (i.e. estimated glomerular filtration rate (eGFR) \>30) Angiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Index of Microcirculatory Resistance (IMR) | Up to 1 hour | Index of Microvascular Resistance (IMR) is defined as the distal coronary pressure multiplied by the hyperaemic mean transit time. IMR = Pd x Tmn at maximal hyperemia. This is for micro vascular function. |
| Fractional Flow Reserve (FFR) | Up to 1 hour | FFR is defined as the ratio of (i.e., percent of normal) flow in the stenotic artery to the flow in the same artery in the theoretic absence of the stenosis. |
| Coronary Flow Reserve (CFR) | Up to 1 hour | Coronary Flow Reserve (CFR) is the ratio between hyperemic and basal coronary flow. CFR=Hyperemic Flow /Resting Flow. This is for micro vascular function. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Troponin I Level | 1 hour | Blood test that helps determine incidence of peri-PCI myonecrosis. |
| Creatinine Kinase (CKMB) Level | 1 hour | Blood test that helps determine incidence of peri-PCI myonecrosis. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Orbital Atherectomy System (OAS) Group OAS was used in percutaneous coronary intervention (PCI) of participants. | 17 |
| Rotational Atherectomy (RA) Group RA was used in percutaneous coronary intervention (PCI) of participants. | 20 |
| Total | 37 |
Baseline characteristics
| Characteristic | Orbital Atherectomy System (OAS) Group | Rotational Atherectomy (RA) Group | Total |
|---|---|---|---|
| Age, Customized ≥ 18 years | 17 Participants | 20 Participants | 37 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 6 Participants | 5 Participants | 11 Participants |
| Sex: Female, Male Male | 11 Participants | 15 Participants | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 20 |
| other Total, other adverse events | 0 / 17 | 0 / 20 |
| serious Total, serious adverse events | 0 / 17 | 0 / 20 |
Outcome results
Primary
Coronary Flow Reserve (CFR)
Coronary Flow Reserve (CFR) is the ratio between hyperemic and basal coronary flow. CFR=Hyperemic Flow /Resting Flow. This is for micro vascular function.
Time frame: Up to 1 hour
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Orbital Atherectomy System (OAS) Group | Coronary Flow Reserve (CFR) | 1.9 ratio |
| Rotational Atherectomy (RA) Group | Coronary Flow Reserve (CFR) | 2.3 ratio |
Primary
Fractional Flow Reserve (FFR)
FFR is defined as the ratio of (i.e., percent of normal) flow in the stenotic artery to the flow in the same artery in the theoretic absence of the stenosis.
Time frame: Up to 1 hour
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Orbital Atherectomy System (OAS) Group | Fractional Flow Reserve (FFR) | 0.85 ratio |
| Rotational Atherectomy (RA) Group | Fractional Flow Reserve (FFR) | 0.88 ratio |
Primary
Index of Microcirculatory Resistance (IMR)
Index of Microvascular Resistance (IMR) is defined as the distal coronary pressure multiplied by the hyperaemic mean transit time. IMR = Pd x Tmn at maximal hyperemia. This is for micro vascular function.
Time frame: Up to 1 hour
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Orbital Atherectomy System (OAS) Group | Index of Microcirculatory Resistance (IMR) | 15 mmHg·s |
| Rotational Atherectomy (RA) Group | Index of Microcirculatory Resistance (IMR) | 25 mmHg·s |
Other Pre-specified
Creatinine Kinase (CKMB) Level
Blood test that helps determine incidence of peri-PCI myonecrosis.
Time frame: 1 hour
Population: Data was not collected due to PI's departure from the institution following completion of data collection for the purposes of the Primary Outcome Measures.
Other Pre-specified
Troponin I Level
Blood test that helps determine incidence of peri-PCI myonecrosis.
Time frame: 1 hour
Population: Data was not collected due to PI's departure from the institution following completion of data collection for the purposes of the Primary Outcome Measures.